{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:51:28Z","timestamp":1794376288770,"version":"4.9.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.xcrm.2025.102257","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T14:35:52Z","timestamp":1753886152000},"page":"102257","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Coupling IL-2 with IL-10 to mitigate toxicity and enhance antitumor immunity"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5168-6717","authenticated-orcid":false,"given":"Julie J.","family":"Ahn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Dudics","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Langan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey D.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice H.","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob C.","family":"McCright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sawyer R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia L.","family":"Castleberry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin I.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier A.","family":"Goit\u00eda V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip N.","family":"Kuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sri Sai Vivek","family":"Alla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Min","family":"Haider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima W.","family":"Hamdan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jhonnatan Esquivel","family":"Ju\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aranganathan","family":"Shanmuganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arielle","family":"Welch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Boclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel A.","family":"Khrimian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher H.","family":"Yaen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6718-774X","authenticated-orcid":false,"given":"John B.","family":"Mumm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2025.102257_bib1","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: the first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.xcrm.2025.102257_bib2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40425-014-0026-0","article-title":"High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014","volume":"2","author":"Dutcher","year":"2014","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2025.102257_bib3","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102257_bib4","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/nri3156","article-title":"The role of interleukin-2 during homeostasis and activation of the immune system","volume":"12","author":"Boyman","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2025.102257_bib5","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1158\/1078-0432.CCR-15-1631","article-title":"NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models","volume":"22","author":"Charych","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102257_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000673","article-title":"ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy","volume":"8","author":"Lopes","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2025.102257_bib7","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1038\/s41467-021-24987-9","article-title":"An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism","volume":"12","author":"Ptacin","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102257_bib8","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/s41467-020-14471-1","article-title":"Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy","volume":"11","author":"Sharma","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102257_bib9","doi-asserted-by":"crossref","first-page":"4756","DOI":"10.1200\/JCO.23.00172","article-title":"Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results","volume":"41","author":"Diab","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102257_bib10","article-title":"A PD-1-targeted, receptor-masked IL-2 immunocytokine that engages IL-2Ralpha strengthens T cell-mediated anti-tumor therapies","volume":"5","author":"Wu","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.xcrm.2025.102257_bib11","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1365-2141.1990.tb07867.x","article-title":"Interleukin-2 treatment-associated eosinophilia is mediated by interleukin-5 production","volume":"76","author":"Macdonald","year":"1990","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.xcrm.2025.102257_bib12","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1182\/blood.V78.6.1538.1538","article-title":"Administration of interleukin-2 (IL-2) results in increased plasma concentrations of IL-5 and eosinophilia in patients with cancer","volume":"78","author":"van Haelst Pisani","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102257_bib13","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/00002371-200211000-00004","article-title":"Regulation of interleukin-2-induced vascular leak syndrome by targeting CD44 using hyaluronic acid and anti-CD44 antibodies","volume":"25","author":"Mustafa","year":"2002","journal-title":"J. Immunother."},{"key":"10.1016\/j.xcrm.2025.102257_bib14","doi-asserted-by":"crossref","first-page":"d665","DOI":"10.2741\/A311","article-title":"Role of CD44 in CTL and NK cell activity","volume":"3","author":"Rafi-Janajreh","year":"1998","journal-title":"Front. Biosci."},{"key":"10.1016\/j.xcrm.2025.102257_bib15","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1182\/blood.V76.10.1933.1933","article-title":"Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects","volume":"76","author":"Mier","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102257_bib16","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40164-025-00638-3","article-title":"Siltuximab for the treatment of early complications after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia in children, adolescents, and young adults","volume":"14","author":"Galan-Gomez","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2025.102257_bib17","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.cell.2020.11.025","article-title":"Synergism of TNF-alpha and IFN-gamma Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes","volume":"184","author":"Karki","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2025.102257_bib18","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1084\/jem.20100414","article-title":"IL-10 inhibits transcription elongation of the human TNF gene in primary macrophages","volume":"207","author":"Smallie","year":"2010","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.xcrm.2025.102257_bib19","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1197458","article-title":"PEG-rIL-10 treatment decreases FoxP3(+) Tregs despite upregulation of intratumoral IDO","volume":"5","author":"Chan","year":"2016","journal-title":"OncoImmunology"},{"key":"10.1016\/j.xcrm.2025.102257_bib20","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1136\/gut.50.2.191","article-title":"Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma","volume":"50","author":"Tilg","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.xcrm.2025.102257_bib21","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.ccr.2011.11.003","article-title":"IL-10 elicits IFN\u03b3-dependent tumor immune surveillance","volume":"20","author":"Mumm","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2025.102257_bib22","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4049\/jimmunol.157.1.231","article-title":"Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice","volume":"157","author":"Berman","year":"1996","journal-title":"J. Immunol."},{"key":"10.1016\/j.xcrm.2025.102257_bib23","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1182\/blood.V98.7.2143","article-title":"Interleukin-10 promotes the maintenance of antitumor CD8(+) T-cell effector function in situ","volume":"98","author":"Fujii","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102257_bib24","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.ccell.2018.10.007","article-title":"PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8(+) T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients","volume":"34","author":"Naing","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2025.102257_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22147652","article-title":"Cytokine Release Syndrome Associated with T-Cell-Based Therapies for Hematological Malignancies: Pathophysiology, Clinical Presentation, and Treatment","volume":"22","author":"Cosenza","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xcrm.2025.102257_bib26","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40364-018-0116-0","article-title":"Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy","volume":"6","author":"Wang","year":"2018","journal-title":"Biomark. Res."},{"key":"10.1016\/j.xcrm.2025.102257_bib27","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.abc0653","article-title":"Engineered IL-10 variants elicit potent immunomodulatory effects at low ligand doses","volume":"13","author":"Gorby","year":"2020","journal-title":"Sci. Signal."},{"key":"10.1016\/j.xcrm.2025.102257_bib28","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1084\/jem.172.6.1625","article-title":"Interleukin 10, a novel B cell stimulatory factor: unresponsiveness of X chromosome-linked immunodeficiency B cells","volume":"172","author":"Go","year":"1990","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.xcrm.2025.102257_bib29","doi-asserted-by":"crossref","first-page":"26586","DOI":"10.1074\/jbc.M112.376707","article-title":"Epstein-Barr virus IL-10 engages IL-10R1 by a two-step mechanism leading to altered signaling properties","volume":"287","author":"Yoon","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.xcrm.2025.102257_bib30","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3389\/fonc.2019.00849","article-title":"Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors","volume":"9","author":"Garcia-Foncillas","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.xcrm.2025.102257_bib31","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abl6322","article-title":"Intrinsic IL-2 production by effector CD8 T cells affects IL-2 signaling and promotes fate decisions, stemness, and protection","volume":"7","author":"Kahan","year":"2022","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.xcrm.2025.102257_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2018.10.017","article-title":"A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease","volume":"95","author":"Peterson","year":"2018","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.xcrm.2025.102257_bib33","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrc3322","article-title":"Paths to stemness: building the ultimate antitumour T cell","volume":"12","author":"Gattinoni","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2025.102257_bib34","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.coi.2021.03.016","article-title":"Modulation of the tumor micro-environment by CD8(+) T cell-derived cytokines","volume":"69","author":"Hoekstra","year":"2021","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.xcrm.2025.102257_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102428","article-title":"Clinical trial data of Anti-PD-1\/PD-L1 therapy for recurrent or metastatic nasopharyngeal Carcinoma: A review","volume":"109","author":"Adkins","year":"2022","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.xcrm.2025.102257_bib36","doi-asserted-by":"crossref","first-page":"5962","DOI":"10.1158\/1078-0432.CCR-11-1209","article-title":"Preclinical pharmacokinetics and safety of Sym004: a synergistic antibody mixture directed against epidermal growth factor receptor","volume":"17","author":"Skartved","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102257_bib37","doi-asserted-by":"crossref","first-page":"33446","DOI":"10.18632\/oncotarget.26002","article-title":"RN765C, a low affinity EGFR antibody drug conjugate with potent anti-tumor activity in preclinical solid tumor models","volume":"9","author":"Wong","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.xcrm.2025.102257_bib38","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1006\/rtph.2001.1504","article-title":"Preclinical safety evaluation of recombinant human interleukin-10","volume":"35","author":"Rosenblum","year":"2002","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.xcrm.2025.102257_bib39","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/BF01741324","article-title":"Production of tumor necrosis factor alpha and interferon gamma in interleukin-2-treated melanoma patients: correlation with clinical toxicity","volume":"34","author":"Economou","year":"1991","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.xcrm.2025.102257_bib40","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1479-5876-2-17","article-title":"Forecasting the cytokine storm following systemic interleukin (IL)-2 administration","volume":"2","author":"Panelli","year":"2004","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.xcrm.2025.102257_bib41","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/cncr.23552","article-title":"High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006","volume":"113","author":"Klapper","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.xcrm.2025.102257_bib42","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abo5409","article-title":"Interleukin-2-based therapies in cancer","volume":"14","author":"Raeber","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2025.102257_bib43","doi-asserted-by":"crossref","first-page":"11906","DOI":"10.1073\/pnas.1002569107","article-title":"Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells","volume":"107","author":"Krieg","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2025.102257_bib44","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41392-023-01452-1","article-title":"Macrophages in immunoregulation and therapeutics","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.xcrm.2025.102257_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1190333","article-title":"Dysregulation in IFN-\u03b3 signaling and response: the barricade to tumor immunotherapy","volume":"14","author":"Han","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2025.102257_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114289","article-title":"Opposing tumor-cell-intrinsic and -extrinsic roles of the IRF1 transcription factor in antitumor immunity","volume":"43","author":"Purbey","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2025.102257_bib47","doi-asserted-by":"crossref","first-page":"4461","DOI":"10.4049\/jimmunol.181.7.4461","article-title":"IFN-gamma-induced TNF-alpha expression is regulated by interferon regulatory factors 1 and 8 in mouse macrophages","volume":"181","author":"Vila-del Sol","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.xcrm.2025.102257_bib48","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/s41419-021-04151-3","article-title":"TNF-alpha synergises with IFN-gamma to induce caspase-8-JAK1\/2-STAT1-dependent death of intestinal epithelial cells","volume":"12","author":"Woznicki","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.xcrm.2025.102257_bib49","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.4049\/jimmunol.147.8.2630","article-title":"IL-6 and IL-6 receptor modulation by IFN-gamma and tumor necrosis factor-alpha in human monocytic cell line (THP-1). Priming effect of IFN-gamma","volume":"147","author":"Sanceau","year":"1991","journal-title":"J. Immunol."},{"key":"10.1016\/j.xcrm.2025.102257_bib50","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41577-022-00680-w","article-title":"Engineering IL-2 for immunotherapy of autoimmunity and cancer","volume":"22","author":"Hernandez","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2025.102257_bib51","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1016\/j.immuni.2024.07.016","article-title":"Interleukin-2 immunotherapy reveals human regulatory T cell subsets with distinct functional and tissue-homing characteristics","volume":"57","author":"Raeber","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2025.102257_bib52","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4049\/jimmunol.155.3.1151","article-title":"Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases","volume":"155","author":"Sakaguchi","year":"1995","journal-title":"J. Immunol."},{"key":"10.1016\/j.xcrm.2025.102257_bib53","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1002\/eji.200939201","article-title":"The role of NF-kappaB and Smad3 in TGF-beta-mediated Foxp3 expression","volume":"39","author":"Jana","year":"2009","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.xcrm.2025.102257_bib54","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1111\/j.1600-6143.2004.00566.x","article-title":"TGF-beta induces Foxp3 + T-regulatory cells from CD4 + CD25 - precursors","volume":"4","author":"Fu","year":"2004","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.xcrm.2025.102257_bib55","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/blood-2007-06-094656","article-title":"Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype","volume":"110","author":"Tran","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102257_bib56","doi-asserted-by":"crossref","first-page":"6329","DOI":"10.4049\/jimmunol.1100061","article-title":"IL-2 controls the stability of Foxp3 expression in TGF-beta-induced Foxp3+ T cells in vivo","volume":"186","author":"Chen","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.xcrm.2025.102257_bib57","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1136\/thx.2005.056317","article-title":"In vivo IL-10 gene delivery attenuates bleomycin induced pulmonary fibrosis by inhibiting the production and activation of TGF-beta in the lung","volume":"61","author":"Nakagome","year":"2006","journal-title":"Thorax"},{"key":"10.1016\/j.xcrm.2025.102257_bib58","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1083\/jcb.124.4.569","article-title":"Interleukin 10 inhibits transforming growth factor-beta (TGF-beta) synthesis required for osteogenic commitment of mouse bone marrow cells","volume":"124","author":"Van Vlasselaer","year":"1994","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.xcrm.2025.102257_bib59","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1200\/JCO.2016.68.1106","article-title":"Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors","volume":"34","author":"Naing","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102257_bib60","doi-asserted-by":"crossref","DOI":"10.20900\/immunometab20210030","article-title":"IL-10-Mediated Refueling of Exhausted T Cell Mitochondria Boosts Anti-Tumour Immunity","volume":"3","author":"Ryan","year":"2021","journal-title":"Immunometabolism"},{"key":"10.1016\/j.xcrm.2025.102257_bib61","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/s41587-023-02060-8","article-title":"IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases","volume":"42","author":"Zhao","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2025.102257_bib62","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41586-022-05192-0","article-title":"PD-1-cis IL-2R agonism yields better effectors from stem-like CD8(+) T cells","volume":"610","author":"Codarri Deak","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102257_bib63","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41586-022-05257-0","article-title":"PD-1 combination therapy with IL-2 modifies CD8(+) T cell exhaustion program","volume":"610","author":"Hashimoto","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102257_bib64","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.it.2023.09.003","article-title":"IL-2-driven CD8(+) T cell phenotypes: implications for immunotherapy","volume":"44","author":"Niederlova","year":"2023","journal-title":"Trends Immunol."},{"key":"10.1016\/j.xcrm.2025.102257_bib65","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adk7640","article-title":"Comparative analysis of Bcl-2 family protein overexpression in CAR T cells alone and in combination with BH3 mimetics","volume":"16","author":"Korell","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2025.102257_bib66","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102257_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114075","article-title":"Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review","volume":"205","author":"Geraud","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.xcrm.2025.102257_bib68","article-title":"TCR-T Immunotherapy: The Challenges and Solutions","volume":"11","author":"Liu","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.xcrm.2025.102257_bib69","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1200\/JCO.21.00612","article-title":"Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma","volume":"39","author":"Sarnaik","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102257_bib70","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16081580","article-title":"T-Cell Engagers-The Structure and Functional Principle and Application in Hematological Malignancies","volume":"16","author":"Cech","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.xcrm.2025.102257_bib71","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1002\/eji.200425485","article-title":"Frontline: An in-depth evaluation of the production of IL-2 by antigen-specific CD8 T cells in vivo","volume":"34","author":"D'Souza","year":"2004","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.xcrm.2025.102257_bib72","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.4049\/jimmunol.172.10.6136","article-title":"IL-2 secretion by CD4+ T cells in vivo is rapid, transient, and influenced by TCR-specific competition","volume":"172","author":"Sojka","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.xcrm.2025.102257_bib73","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.67","article-title":"Interferon-\u03b3 derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity","volume":"8","author":"Bhat","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.xcrm.2025.102257_bib74","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/s41586-023-06721-1","article-title":"Epithelial IFN\u03b3 signalling and compartmentalized antigen presentation orchestrate gut immunity","volume":"623","author":"Malik","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102257_bib75","doi-asserted-by":"crossref","first-page":"5835","DOI":"10.1074\/jbc.274.9.5835","article-title":"CD40 signaling of monocyte inflammatory cytokine synthesis through an ERK1\/2-dependent pathway. A target of interleukin (il)-4 and il-10 anti-inflammatory action","volume":"274","author":"Suttles","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.xcrm.2025.102257_bib76","article-title":"The bioconjugation and radiosynthesis of 89Zr-DFO-labeled antibodies","volume":"96","author":"Zeglis","year":"2015","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.xcrm.2025.102257_bib77","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1162\/153535003322556877","article-title":"AMIDE: a free software tool for multimodality medical image analysis","volume":"2","author":"Loening","year":"2003","journal-title":"Mol. Imaging"}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125003301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125003301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T21:41:02Z","timestamp":1762638062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379125003301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":77,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2666379125003301"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102257","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Coupling IL-2 with IL-10 to mitigate toxicity and enhance antitumor immunity","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102257","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Deka Biosciences. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102257"}}